Literature DB >> 26945671

Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.

Alok K Sharma1,2,3, David J Friedman1,2,3, Martin R Pollak1,3, Seth L Alper1,2,3.   

Abstract

Trypanosomes that cause sleeping sickness endocytose apolipoprotein L1 (APOL1)-containing trypanolytic factors from human serum, leading to trypanolytic death through generation of APOL1-associated lytic pores in trypanosomal membranes. The trypanosome Trypanosoma brucei rhodesiense counteracts trypanolysis by expressing the surface protein serum response-associated (SRA), which can bind APOL1 common variant G0 to block its trypanolytic activity. However, two missense variants in the C terminal predicted coiled-coil (CC) domains of human APOL1 G1 (S342G/I384M) and G2 (ΔN388Y389) decrease or abrogate APOL1 binding to T. brucei rhodesiense SRA, thus preserving APOL1 trypanolytic activity. These evolutionarily selected APOL1 missense variants, found at a high frequency in some populations of African descent, also confer elevated risk of kidney disease. Understanding the SRA-APOL1 interaction and the role of APOL1 G1 and G2 variants in kidney disease demands structural characterization of the APOL1 CC domain. Using CD, heteronuclear NMR, and molecular dynamics (MD) simulation on structural homology models, we report here unique and dynamic solution conformations of nephropathy variants G1 and G2 as compared with the common variant G0. Conformational plasticity in G1 and G2 CC domains led to interhelical α1-α2 approximation coupled with secondary structural changes and delimited motional properties absent in the G0 CC domain. The G1 substitutions conferred local structural changes principally along helix α1, whereas the G2 deletion altered the structure of both helix α2 and helix α1. These dynamic features of APOL1 CC variants likely reflect their intrinsic structural properties, and should help interpret future APOL1 structural studies and define the contribution of APOL1 risk variants to kidney disease.
© 2016 Federation of European Biochemical Societies.

Entities:  

Keywords:  Trypanosoma brucei rhodesiense; circular dichroism; kidney disease; molecular dynamics simulation; nuclear magnetic resonance

Mesh:

Substances:

Year:  2016        PMID: 26945671      PMCID: PMC4879057          DOI: 10.1111/febs.13706

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  45 in total

1.  Expression, purification, and characterization of coiled coil and leucine zipper domains of C-terminal myosin binding subunit of myosin phosphatase for solution NMR studies.

Authors:  Alok K Sharma; Paramvir Sawhney; Gonen Memisoglu; Alan C Rigby
Journal:  Protein Expr Purif       Date:  2011-10-07       Impact factor: 1.650

2.  Improving protein fold recognition and template-based modeling by employing probabilistic-based matching between predicted one-dimensional structural properties of query and corresponding native properties of templates.

Authors:  Yuedong Yang; Eshel Faraggi; Huiying Zhao; Yaoqi Zhou
Journal:  Bioinformatics       Date:  2011-06-11       Impact factor: 6.937

3.  RaptorX: exploiting structure information for protein alignment by statistical inference.

Authors:  Jian Peng; Jinbo Xu
Journal:  Proteins       Date:  2011-10-11

4.  Improved sensitivity of HSQC spectra of exchanging protons at short interscan delays using a new fast HSQC (FHSQC) detection scheme that avoids water saturation.

Authors:  S Mori; C Abeygunawardana; M O Johnson; P C van Zijl
Journal:  J Magn Reson B       Date:  1995-07

Review 5.  The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus.

Authors:  Saharon Rosset; Shay Tzur; Doron M Behar; Walter G Wasser; Karl Skorecki
Journal:  Nat Rev Nephrol       Date:  2011-05-03       Impact factor: 28.314

6.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

Review 7.  APOL1 and kidney disease.

Authors:  Martin R Pollak; Giulio Genovese; David J Friedman
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-03       Impact factor: 2.894

8.  Evolution of the primate trypanolytic factor APOL1.

Authors:  Russell Thomson; Giulio Genovese; Chelsea Canon; Daniella Kovacsics; Matthew K Higgins; Mark Carrington; Cheryl A Winkler; Jeffrey Kopp; Charles Rotimi; Adebowale Adeyemo; Ayo Doumatey; George Ayodo; Seth L Alper; Martin R Pollak; David J Friedman; Jayne Raper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-07       Impact factor: 11.205

9.  Synthetic model proteins. Positional effects of interchain hydrophobic interactions on stability of two-stranded alpha-helical coiled-coils.

Authors:  N E Zhou; C M Kay; R S Hodges
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

Review 10.  The molecular arms race between African trypanosomes and humans.

Authors:  Etienne Pays; Benoit Vanhollebeke; Pierrick Uzureau; Laurence Lecordier; David Pérez-Morga
Journal:  Nat Rev Microbiol       Date:  2014-06-30       Impact factor: 60.633

View more
  12 in total

Review 1.  ApoL1 and the Immune Response of Patients with Systemic Lupus Erythematosus.

Authors:  Ashira D Blazer; Robert M Clancy
Journal:  Curr Rheumatol Rep       Date:  2017-03       Impact factor: 4.592

Review 2.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

3.  A null variant in the apolipoprotein L3 gene is associated with non-diabetic nephropathy.

Authors:  Karl L Skorecki; Jessica H Lee; Carl D Langefeld; Saharon Rosset; Shay Tzur; Walter G Wasser; Revital Shemer; Gregory A Hawkins; Jasmin Divers; Rulan S Parekh; Man Li; Matthew G Sampson; Matthias Kretzler; Martin R Pollak; Shrijal Shah; Daniel Blackler; Brendan Nichols; Michael Wilmot; Seth L Alper; Barry I Freedman; David J Friedman
Journal:  Nephrol Dial Transplant       Date:  2018-02-01       Impact factor: 5.992

4.  APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes.

Authors:  Etty Kruzel-Davila; Revital Shemer; Ayala Ofir; Ira Bavli-Kertselli; Ilona Darlyuk-Saadon; Pazit Oren-Giladi; Walter G Wasser; Daniella Magen; Eid Zaknoun; Maya Schuldiner; Adi Salzberg; Daniel Kornitzer; Zvonimir Marelja; Matias Simons; Karl Skorecki
Journal:  J Am Soc Nephrol       Date:  2016-11-18       Impact factor: 10.121

5.  The Relationship between APOL1 Structure and Function: Clinical Implications.

Authors:  Sethu M Madhavan; Matthias Buck
Journal:  Kidney360       Date:  2020-11-04

6.  APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8.

Authors:  Sethu M Madhavan; John F O'Toole; Martha Konieczkowski; Laura Barisoni; David B Thomas; Santhi Ganesan; Leslie A Bruggeman; Matthias Buck; John R Sedor
Journal:  JCI Insight       Date:  2017-07-20

7.  Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes.

Authors:  Nidhi Gupta; Xinhua Wang; Xiaohui Wen; Paul Moran; Maciej Paluch; Philip E Hass; Amy Heidersbach; Benjamin Haley; Daniel Kirchhofer; Randall J Brezski; Andrew S Peterson; Suzie J Scales
Journal:  J Am Soc Nephrol       Date:  2020-08-06       Impact factor: 10.121

Review 8.  Apolipoprotein L1 nephropathies: 2017 in review.

Authors:  Jeffrey B Kopp; Hila Roshanravan; Koji Okamoto
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-05       Impact factor: 2.894

9.  APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin.

Authors:  Sophie Uzureau; Laurence Lecordier; Pierrick Uzureau; Dorle Hennig; Jonas H Graversen; Fabrice Homblé; Pepe Ekulu Mfutu; Fanny Oliveira Arcolino; Ana Raquel Ramos; Rita M La Rovere; Tomas Luyten; Marjorie Vermeersch; Patricia Tebabi; Marc Dieu; Bart Cuypers; Stijn Deborggraeve; Marion Rabant; Christophe Legendre; Søren K Moestrup; Elena Levtchenko; Geert Bultynck; Christophe Erneux; David Pérez-Morga; Etienne Pays
Journal:  Cell Rep       Date:  2020-03-17       Impact factor: 9.423

10.  Structures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif.

Authors:  Mark Ultsch; Michael J Holliday; Stefan Gerhardy; Paul Moran; Suzie J Scales; Nidhi Gupta; Francesca Oltrabella; Cecilia Chiu; Wayne Fairbrother; Charles Eigenbrot; Daniel Kirchhofer
Journal:  Commun Biol       Date:  2021-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.